EGFR and non-small cell lung carcinoma: Previous reports described an anti-proliferative or pro-apoptotic effect of Ibrutinib in EGFR-mutated NSCLC cells [34–36] that was attributed to the inhibition of mutated EGFR by Ibrutinib.